Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
- Generic Name
- Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
- Brand Names
- Adacel, Boostrix, Daptacel, Diphtheria and Tetanus Toxoids Adsorbed, Infanrix, Kinrix, Pediarix, Pentacel, Quadracel, Td Adsorbed, Tdvax, Tenivac, Vaxelis
- Drug Type
- Biotech
- CAS Number
- 308079-75-6
- Unique Ingredient Identifier
- IRH51QN26H
- Associated Conditions
- Diphtheria, Tetanus
Sanofi Aims to Expand Atopic Dermatitis Market Presence with Novel Therapies
• Sanofi's Dupixent achieved over $13 billion in global sales, establishing it as a gold standard in atopic dermatitis (AD) treatment.
• Sanofi is developing SAR444656 (KT-474), an IRAK4 degrader in Phase II trials, in collaboration with Kymera Therapeutics, with data expected in H1 2025.
• Amlitelimab, an anti-OX40L monoclonal antibody, is in Phase III trials, showing promise in reshaping the AD treatment landscape and increasing competition.
• Sanofi's strategic focus on innovation and pipeline development aims to maintain its competitive edge in the expanding atopic dermatitis market.
Sanofi's Q3 Sales Surge 15.7% Driven by Vaccines and Dupixent; 2024 EPS Guidance Raised
• Sanofi reported a robust 15.7% sales growth in Q3, fueled by strong vaccine sales and the continued success of Dupixent, with sales up 23.8% to €3,476 million.
• Pharma launches, including ALTUVIIIO, Nexviazyme, and Rezurock, saw a significant 67.1% increase, contributing €727 million to the overall sales growth.
• The company's pipeline advanced with four regulatory approvals, including Dupixent for COPD in the US and China, and four positive Phase 3 data readouts, including tolebrutinib for nrSPMS.
• Based on strong Q3 business performance, Sanofi has raised its 2024 business EPS guidance to at least a low single-digit percentage growth at CER.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath